Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Operating Margin: 2022-2025

Historic Operating Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -158.56%.

  • bioAffinity Technologies' Operating Margin fell 7458.00% to -158.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -153.20%, marking a year-over-year decrease of 6407.00%. This contributed to the annual value of -95.64% for FY2024, which is 21920.00% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Operating Margin of -158.56% as of Q3 2025, which was up 19.98% from -198.16% recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Operating Margin high stood at 59.61% for Q2 2022, and its period low was -169,160.69% during Q1 2023.
  • For the 3-year period, bioAffinity Technologies' Operating Margin averaged around -16,357.17%, with its median value being -141.73% (2025).
  • In the last 5 years, bioAffinity Technologies' Operating Margin slumped by 906,939bps in 2023 and then skyrocketed by 16,907,986bps in 2024.
  • Over the past 4 years, bioAffinity Technologies' Operating Margin (Quarterly) stood at -69,213.17% in 2022, then soared by 6,910,734bps to -105.83% in 2023, then tumbled by 2,764bps to -133.47% in 2024, then plummeted by 7,458bps to -158.56% in 2025.
  • Its last three reported values are -158.56% in Q3 2025, -198.16% for Q2 2025, and -141.73% during Q1 2025.